Shares of HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) are up 13% after the company this morning said it has been issued two new U.S. patents by the United States Patent and Trademark Office covering the company’s technology and applications of its technology. The first patent, entitled Molecular Malignancy in Melanocytic Lesions (U.S. Patent 9,758,829), was issued to HTG and the John Wayne Cancer Institute, who co-invented the technology. The patent claims a method of treatment on an indeterminate or atypical nevi that involves measuring the nucleic acid expression of certain biomarkers, including MAGEA2, PRAME, PDIA4, NR4A1, PDLIM7, B4GALT1, SAT1, RUNX1, and SOCS3. The patent will expire in June 2033. The second patent, entitled Nuclease Protection Methods for Detection of Nucleotide Variants (U.S. Patent No. 9,765,385), claims a nuclease-protection-based method for targeted detection of single nucleotide variants. The patent expires in October 2033. “The newly issued patents substantiate the proprietary nature of our business and represent an important step in protecting our technology and its applications,” HTG chief executive officer TJ Johnson stated in the news release.
To view the full press release, visit: http://nnw.fm/Bw1zo
About HTG
Headquartered in Tucson, Arizona, the mission of HTG Molecular Diagnostics (HTG) is to empower precision medicine at the local level. The company’s HTG EdgeSeq technology, which automates highly multiplexed molecular profiling of minute samples for next-generation sequencing, received its first U.S. patent in 2014. Continuous improvements led to the 2017 launch of HTG’s new direct-target sequencing chemistry for DNA analysis offered in the company’s VERI/O services laboratory. Additional information is available at www.htgmolecular.com.
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
